ArticleBMC public health2023
The burden of Parkinson's disease in the Middle East and North Africa region, 1990-2019: results from the global burden of disease study 2019.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06612593 (The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Parkinson's disease in the United Arab Emirates (UAE): Emirates Neurology Society consensus guidelines.Frontiers in neurology · 2026Guideline
- Insights into Parkinson's Disease-Related Freezing of Gait Detection and Prediction Approaches: A Meta Analysis.Sensors (Basel, Switzerland) · 2024Pooled it
- Progressive Cognitive Decline and Pyramidal Signs in a Patient With a Novel Homozygous c.395A>T; p.Lys132Met Mutation in CHCHD2.Clinical case reports · 2026Article
- Breaking barriers and fighting inequality in Parkinson's disease care: Personal reflections of movement disorders clinicians.Journal of Parkinson's disease · 2026Article
- Review
- Metabolic stress exacerbates Parkinson's disease pathology through mitochondrial dysfunction and ferroptosis.NPJ Parkinson's disease · 2026Article
- Depression and anxiety among patients with Parkinson's disease: A cross-sectional study in a Saudi population.Medicine · 2026Article
- Correlations Between Clinical, Anthropometric and Nutritional Evaluations in Patients with Parkinson's Disease from Ghana: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- National and subnational burden of neurological disorders in Iran, 1990 to 2021: results from the global burden of disease study 2021.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Epidemiology of movement disorders in the adult population of Qatar: Prevalence, types, and demographics.Qatar medical journal · 2026Article
- Differential Proteomic Landscape of Plasma Neuron-Derived Extracellular Vesicles in Parkinson's Disease with and without RBD: A Pilot Investigation.International journal of nanomedicine · 2026Article
- Access to Parkinson's disease treatments in the Middle East: a multi-national survey of availability, affordability, and utilization patterns.Clinical parkinsonism & related disorders · 2026Article
- Knowledge and Misconceptions About Parkinson's Disease in Lebanon: A Cross-Sectional Survey.Parkinson's disease · 2026Article
- Voice fundamental characteristics in Parkinson's disease: a case-control study of the Moroccan population.Neurodegenerative disease management · 2025Article
- IntravenousJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy.Chinese medicine · 2025Article
- Article
- A report of the Iranian Parkinson's disease registry.NPJ Parkinson's disease · 2025Article
- Global, regional, and national epidemiology of neurological disorders and subcategories: incidence and disability-adjusted life years, 1990-2021.European journal of medical research · 2025Article
- Burden of Parkinson's disease in Iran: disparities, trends, and the impact of social development indicators.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) remains a common disabling progressive neurodegenerative disorder. We aimed to report the prevalence, death and disability-adjusted life-years (DALYs) attributable to PD in the Middle East and North Africa (MENA) region and its 21 countries by age, sex and socio-demographic index (SDI), between 1990 and 2019.
methodsPublicly available data on the burden of PD in the MENA countries were retrieved from the Global Burden of Disease (GBD) 2019 project. The results are presented with age-standardised numbers and rates per 100,000 population, along with their corresponding 95% uncertainty intervals (UIs).
resultsIn 2019, PD had an age-standardised point prevalence of 82.6 per 100,000 population in MENA and an age-standardised death rate of 5.3, which have increased from 1990 to 2019 by 15.4% and 2.3%, respectively. In 2019, the age-standardised DALY rate of PD was 84.4, which was 0.9% higher than in 1990. The highest and lowest age-standardised DALY rates of PD in 2019 were found in Qatar and Kuwait, respectively. Also in 2019, the highest number of prevalent cases and number of DALYs were found in the 75-79 age group for both sexes. In 2019, females in MENA had an overall higher DALY rate. Furthermore, from 1990 to 2019 the burden of PD generally decreased with increasing socio-economic development, up to an SDI of around 0.4, and then increased with higher levels of SDI.
conclusionAn upward trend was observed in the point prevalence of PD over the last three decades. This highlights the need to allocate more resources for research. Furthermore, properly equipped healthcare services are needed for the increasing number of patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.